TerraPower Isotopes Congratulates Cardinal Health on Milestone

December 20, 2024

“Congratulations to Cardinal Health on this incredible achievement! Today, they announced the start of weekly production of actinium-225 (Ac-225) through their Center for Theranostics Advancement in Indianapolis,” said Scott Claunch, President of TerraPower Isotopes. “This milestone is a major step forward in precision medicine and holds great promise for advancing new cancer treatments. TerraPower Isotopes is proud to collaborate with Cardinal Health and support their groundbreaking work in this critical field.

TPI’s commitment and success in providing commercial access to actinium-225 to drug developers and for use in radiopharmaceutical human clinical trials is possible because of the skilled, dedicated radiochemists at TerraPower Isotopes and our partnerships with Isotek and the Department of Energy, as well as collaborations with organizations like Cardinal Health. I’m proud our work is catalyzing the increased production of actinium-225.”

Subscribe

Be the first to hear about TerraPower's latest innovations, partnerships and breakthroughs.